+1 - Solvay

Fair value differences
These record the marking to market of listed securities and financial derivatives used for hedging purposes.
In 2007, the negative variation of EUR 248 million is due principally to the fall in the share price of our shareholding
in Fortis (EUR 182 million) and the taking into income of part of the latent capital gain on Sofina (EUR 66 million)
when selling our shares on the stock market.
The fair value differences include also the marking to market of financial instruments accounted for according to
IAS 39 as cash flow hedges. Only the effective part of the hedge is recognized in equity, with the balance being
taken directly into income. The variation in this effective part, recognized among fair value differences, amounted
to EUR 7 million at the end of 2007 (End 2006: EUR 7 million).
When the financial instrument designated as a hedge matures, its value recognized in equity is transferred to
the income statement. In 2007, EUR 7 million was transferred from equity to the income statement.
Minority interests
“Income and expenses directly allocated to equity” reduced by EUR 39 million, due to the transfer to the income
statement of the latent capital gain on Sofina (EUR 37 million).
The “other” caption contains a EUR 71 million reduction, which represents the repayment of capital of Société
Financière Keyenveld S.A. to the third party shareholder through the contribution of Sofina shares.
Number of shares (in thousands) 1
Shares issued and fully paid in at 1/1/2007 84 701
Capital increase 0
Shares issued and fully paid in at 31/12/2007 84 701
Own shares held at 31/12/2007 2 638
Shares authorized but not yet issued 0
Par value 15 EUR / share
1 See the consolidated data per share in the financial infromation per share given in the Management Report.
Information on the dividend proposed to the Shareholders’ Meeting can be found in the Management Report.
Financial
Solvay Global Annual Report 2007
69